First of Three Patents Issued

February 17, 2020

Over the past two years, MSA has worked closely with Bryn Pharma to develop a new system for delivering epinephrine to treat patients suffering from severe allergic reactions. This new approach will include a nasal delivery system containing a new formulation of epinephrine. This novel formulation is designed for nasal delivery and was a subject of a series of pre-clinical studies that provided the basis for three patent applications. The first of the patents have been issued, with the remaining two still pending.  Named on the patent are MSA Principals, Kenneth Dretchen, Ph.D., and Michael Mesa, along with MSA associate Matt Robben Ph.D.